BioSpace News Archive

AIDS Healthcare Foundation (AHF), the world’s largest provider of HIV/AIDS care globally, fully supports a recent call in an editorial by The Lancet journal for the appointment of a high-level leader or a group with a moral and authoritative voice to act as a liaison between countries in ensuring equitable and fair access to COVID-19 vaccines around the world.

Methicillin Resistant Staphylococcus aureus is the most prevalent multi-drug resistant bacteria and a growing threat to health.

Transdermal and transmucosal drug delivery systems as alternative drug delivery routes have gained traction in clinical practices over the past few decades.

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that it has expanded its previously-announced AdCOVID manufacturing collaboration with Lonza.

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels

Lanadelumab is an investigational monoclonal antibody for the preventive treatment of hereditary angioedema (HAE) in patients 12 years and older

Allelica, a leading genomics software company specialising in developing polygenic risk scores for common diseases, announced that the company has raised $1.75 million in a seed financing round led by Valor Ventures, Sternberg Health, Pi Campus, as well as strategic business angels also participated in the round.

Brominated flame retardants are found in furniture, electronics, and kitchenware to slow the spread of flames in the event of a fire.

Swedish Orphan Biovitrum AB announces that the first patient has been dosed with avatrombopag, a thrombopoietin receptor agonist, for treatment of immune thrombocytopenia in pediatric patients.

HepaTx Corporation, Namocell Inc., and Takara Bio USA, Inc. announced successful completion of the second phase of their collaboration on single cell analysis of hepatocyte-like cells differentiated from adipose tissue-derived stromal cells using Namocell’s Single Cell Dispensers and Takara Bio’s SMART-seq® kits to characterize HepaTx’s novel cell therapies for liver disease.